Search Medical Condition
Please enter condition
Please choose location from dropdown

Bergamo, Italy Clinical Trials

A listing of Bergamo, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (159) clinical trials

Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these ...

Phase N/A

0.0 miles

Learn More »

Research Tissue Bank

This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: Peripheral blood Bone marrow Bone marrow biopsy A phlebotomized unit of blood Spleen cells Toenail clippings This material will be used for the study of Myeloproliferative Disorders (MPD) by ...

Phase N/A

0.0 miles

Learn More »

Optical Coherence Tomography for Drug Eluting Stent Safety

If overlapping drug-eluting stents provide increased vessel toxicity is not known. Given the association of delayed healing and incomplete endothelialization observed in animal and human autopsy studies at overlapping sites it is unclear why most patients do well with multiple DES implanted. OCT detecs smaller degrees of in-stent neointima more ...

Phase

0.0 miles

Learn More »

Agili-C Implant Performance Evaluation

This is a prospective, multicenter, open-label, randomized, and controlled trial of Agili-C vs. SSOC for the repair of joint surface lesions. Follow-up visits will be performed at 2 weeks and at 3, 6, 12, 18 and 24 months post-procedure to evaluate the patient's knee condition and clinical health. The following ...

Phase N/A

0.0 miles

Learn More »

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Phase

0.0 miles

Learn More »

Safety Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S. aureus) bloodstream infections (bacteremia), including endocarditis in adults. Patients will be randomized to receive a single ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy

The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Phase

0.0 miles

Learn More »

RED-FLAGS Index Validation in Crohn's Disease Patients

The study will be conducted in Italian referral centers for Crohn's disease and will involve general practitioners (GPs) for RED-Flags Index validation. The project is divided into two phases. retrospective phase (4 weeks). All the general practitioners participating to the study will extrapolate from their patient's database, the total number ...

Phase N/A

0.0 miles

Learn More »

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD

To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

Phase

0.0 miles

Learn More »

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), ...

Phase

0.0 miles

Learn More »